Form 4 for SRPT Sarepta Therapeutics, Inc.
Accepted 2023-11-20 00:00:00 ET · period of report 2023-11-17 · accession 0001209191-23-056168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-20 | 2023-11-17 | SRPT | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $82.98 | -4,508 | 65.8K | -6% | -$374.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-17 | F | D | 4,508 | $82.98 | 65,751 | D | — | — | (F1) Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021. (F2) Amount of Securities Beneficially Owned includes 89 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2023. |